Mendy J. Ter Avest - Publications

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency.

Journal: British journal of clinical pharmacology

Published: December 22, 2025

Atypical Hemolytic Uremic Syndrome in Children and Adults With the Hot Spot C3 Gene Variant p.Arg161Trp.

Journal: Kidney international reports

Published: December 16, 2025

Tailoring Eculizumab Treatment: Evaluation of Model-Informed Precision Dosing for Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome.

Journal: Therapeutic drug monitoring

Published: October 01, 2025

Model-Informed Precision Dosing of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Journal: Clinical pharmacokinetics

Published: May 22, 2025

Model-informed repurposing of eliglustat for treatment and prophylaxis of Shiga toxin-producing Escherichia coli hemolytic-uremic syndrome (STEC-HUS) in children.

Journal: Pediatric nephrology (Berlin, Germany)

Published: December 03, 2024

Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: July 16, 2024

Differential effects of C5 inhibition, C3 inhibition, and alternative pathway inhibition on bacterial killing in vitro.

Journal: Blood advances

Published: May 07, 2024

Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan.

Journal: Annals of hematology

Published: May 31, 2023

Proteinuria and Exposure to Eculizumab in Atypical Hemolytic Uremic Syndrome.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: October 14, 2022

Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness.

Journal: British journal of clinical pharmacology

Published: September 02, 2022

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study.

Journal: Kidney international reports

Published: July 05, 2022

Don't stop medication too abruptly: advice about the discontinuation of medication

Journal: Nederlands tijdschrift voor geneeskunde

Published: December 02, 2021